Vote Scores

Home / Companies / Regeneron Pharmaceuticals, Inc. / 14 Jun 2024

Meeting · year to 30 June 20241,313 filers reporting

Regeneron Pharmaceuticals, Inc.: meeting of 14 Jun 2024

Votes reported on Form N-PX, item by item

1,313 Form N-PX filers reported votes at the Regeneron Pharmaceuticals, Inc. meeting of 14 Jun 2024. Their records fall into 6 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.

foragainstabstain, withhold or otheramber tick: the portion cast against management

Items

1

DIRECTOR ELECTIONSIssuer

Director elections

5 nominees; 85.5% of reported votes for; 225 filers withheld from or voted against at least one nominee.

5,319 vote records from 382 filers. 11 of the 379 filers that marked the item either way voted against management. 3 filers reported this item without a management mark.

96.3% for2.6% against1.0% other2.9% against management382 filers
2

SECTION 14A SAY-ON-PAY VOTESIssuer

Advisory vote on executive pay (say-on-pay)

2,227 vote records from 1,283 filers. 70 of the 1,250 filers that marked the item either way voted against management. 33 filers reported this item without a management mark.

0 filers reported share counts too large to be the holding described. No share split is published for this item. How that is decided

91.7% for5.4% against2.9% other5.6% against management1,283 filers
3

AUDIT-RELATEDIssuer

Audit-related items (auditor ratification)

1,063 vote records from 380 filers. 14 of the 377 filers that marked the item either way voted against management. 3 filers reported this item without a management mark.

95.3% for3.7% against1.1% other3.7% against management380 filers99.7% for0.2% against0.0% other0.3% against management48,791,008 reported shares
4

COMPENSATIONIssuer

COMPENSATION: management items

Management items in this category are shown together; filers word and number them differently.

56 vote records from 28 filers. 3 of the 28 filers that marked the item either way voted against management.

85.7% for10.7% against3.6% other10.7% against management28 filers99.0% for0.9% against0.1% other0.9% against management98,712 reported shares, counted once per item in this group
5

CORPORATE GOVERNANCESecurity holder

Non-binding shareholder proposal requesting simple majority voting requirements

1,021 vote records from 371 filers. 340 of the 369 filers that marked the item either way voted against management. 2 filers reported this item without a management mark.

91.4% for8.1% against0.5% other92.1% against management371 filers98.4% for1.5% against0.0% other98.5% against management47,884,728 reported shares
6

Several categoriesSecurity holder

Shareholder proposals (not separable from the filings)

Filers described these proposals in wordings that could not be matched to one another, so they are shown together.

4 vote records from 4 filers. 2 of the 4 filers that marked the item either way voted against management.

50.0% for50.0% against50.0% against management4 filers81.7% for18.2% against0.1% other81.8% against management5,867 reported shares, counted once per item in this group

How the largest families voted

Family1. Directors2. Say-on-pay3. Auditor5. Proposal
VanguardForForForFor *
BlackRock and iSharesForForForFor *
FidelityForForForFor *
DimensionalForForForFor *
State Street and SPDRForForForFor *
American CenturyForForForFor *
Franklin TempletonForForForFor *
InvescoForForForFor *
EquitableForForForFor *
Charles SchwabForForForFor *
Nuveen and TIAAForForForFor *
ProShares and ProFundsForForForFor *
John Hancock and ManulifeForForForFor *
Morgan Stanley, Eaton Vance and CalvertForAgainst *ForFor *
J.P. MorganForForForFor *
Goldman SachsForForForFor *
WisdomTreeForForForFor *
PGIM and PrudentialForForForFor *
Jackson National fundsForForForFor *
Northern Trust and FlexSharesForForForFor *
SEIForForForFor *
T. Rowe PriceAgainst *ForForAgainst
ThriventForForForFor *
Lincoln FinancialForForForFor *
VoyaForForForFor *
First TrustForForForFor *
Russell InvestmentsForForForFor *
NationwideForForForFor *
Victory CapitalForForForFor *
Brighthouse FundsForForForFor *
Guggenheim and RydexForForForFor *
Columbia ThreadneedleForForForFor *
BNY MellonForForAgainst *For *
PrincipalForForForFor *
Capital Group and American FundsForForForFor *
Pacific Life fundsForForForFor *
Global XForForForNo report
MFSForForForFor *
TransamericaForForForFor *
Federated HermesForForForFor *
AllianceBernsteinForForForFor *
Hartford FundsForForForFor *
DWSForForForFor *
PIMCOAgainst *ForAgainst *For *
AllspringForForForFor *
MassMutualForForForFor *
Harbor FundsForForForFor *
VirtusForForForFor *
VanEckForForForFor *
Macquarie and Delaware FundsForForForFor *
Janus HendersonForForForFor *
Neuberger BermanNo reportForNo reportNo report
Natixis and Loomis SaylesForForForFor *
Lord AbbettForForForFor *
Dodge & CoxForForForFor *
Harris Associates and OakmarkNo reportForNo reportNo report
BairdForForForFor *

* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.

Questions

How did large funds vote at the Regeneron Pharmaceuticals, Inc. meeting?

1,313 Form N-PX filers reported votes at the meeting of 14 Jun 2024. On say-on-pay, 70 of 1,250 voted against management (5.6%). One proposal from security holders could be told apart in the filings. The family table lists each of the largest families item by item.

Is this the meeting result?

No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Regeneron Pharmaceuticals, Inc. on Form 8-K.

Why are director elections shown as counts only?

Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.

Every meeting on file for Regeneron Pharmaceuticals, Inc.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Regeneron Pharmaceuticals, Inc. with a meeting date within three days of 14 Jun 2024. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.